Test Price
1,800 AED✅ Home Collection Available
NPM1 & CEBPA Mutation Analysis in UAE – 1,800 AED | DHA Licensed Genetics Panel
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity via Sanger sequencing – ISO 9001:2015 accredited process for reliable mutation detection in acute myeloid leukemia (AML).
- Extraction Protocol: Hospital extraction only – sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Support: Complimentary telephonic post-test consultation with a Consultant Medical Geneticist to correlate results with clinical history.
- Insurance & Billing: Direct billing verification via WhatsApp: +971 54 548 8731 prior to sample collection.
Test Overview & Methodology
The NPM1+ CEBPA mutation analysis is a targeted DNA sequencing test that identifies somatic mutations in the NPM1 and CEBPA genes. This dual-gene panel is essential for diagnostic workup, prognostic stratification, and minimal residual disease monitoring of AML. Results are available within 7–8 days using gold-standard Sanger sequencing of the full coding region.
| Feature | Our Test – AMLexpert™ UAE | Alternative Laboratory |
|---|---|---|
| Methodology | Sanger sequencing – full coding region (gold standard) | qPCR / fragment analysis (limited coverage) |
| Sensitivity | Detects mutations down to 5% mutant allele frequency | Often 10–20% – may miss low-level clones |
| Turnaround Time | 7–8 days | 10–14 days |
| Sample Stability | Cold-chain logistics, immediate transport | Uncontrolled collection, delayed processing |
Physician Insight & Safety Protocols
“A negative NPM1 or CEBPA result does not exclude AML; these findings must always be correlated with bone marrow morphology, cytogenetics, and clinical presentation. This test is crucial for risk stratification, but treatment decisions—especially for favourable-risk NPM1-mutated AML—should be made after multidisciplinary review. As a Consultant Medical Geneticist, I emphasise the importance of genetic counselling for patients and families.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠ Medication Advisory
Do not discontinue prescribed medication (e.g., hydroxyurea, lenalidomide, or targeted therapy) without consulting your treating physician. This test is for mutation profiling only and does not replace therapeutic monitoring.
🚨 Exclusion Criteria & Emergency Red Flags
- Active uncontrolled infection or fever > 38.5°C – postpone collection until stabilised.
- Patients on anticoagulants (except aspirin) require physician clearance for bone marrow aspiration.
- Seek immediate emergency care if you experience severe bruising, persistent bleeding at the site, or sudden shortness of breath after sample collection.
- This test is not intended for paediatric patients without DHA-approved parental consent (refer to Federal Decree-Law No. 4 of 2016 on Medical Liability).
Patient FAQ & Clinical Guidance
1. What is the clinical utility of NPM1+ CEBPA mutation testing?
This test detects mutations in the NPM1 and CEBPA genes to guide prognosis and treatment in acute myeloid leukemia. Results help haematologists determine whether you belong to a favourable, intermediate, or adverse risk group, directly influencing chemotherapy intensity and stem cell transplant timing.
2. How should I prepare for sample collection, and what specimens are accepted?
You must provide a valid doctor’s prescription; no special fasting is required but immediate transport is mandatory. The test uses bone marrow aspirate or peripheral blood collected in EDTA tubes and must be processed within 24 hours under cold-chain conditions. This is a hospital-only procedure – collection occurs within an accredited hospital facility.
3. Are there legal or insurance considerations specific to UAE patients?
This test requires a DHA-licensed physician’s prescription. Insurance pre-approval can be verified via WhatsApp before the visit. All genetic data is encrypted and processed solely within the UAE in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
UAE Regulatory & Data Privacy Adherence
Data Protection: All patient data is handled in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 on the Use of ICT in Health Fields. Genetic information is encrypted, stored within UAE borders, and accessible only to authorised clinical personnel.
Medical Liability & Consent: Sample collection and testing follow the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability. Informed consent is obtained prior to any invasive procedure.
Accreditation: ISO 9001:2015 Certified (INT/EGQ/2509DA/3139). DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | NPM1 & CEBPA Mutation Analysis (Sanger Sequencing) |
| Price (AED) | 1,800 |
| Turnaround Time | 7–8 business days |
| Sample Type / Matrix | Bone marrow aspirate or peripheral blood (EDTA) – Hospital extraction only |
| Methodology Used | Sanger sequencing – full coding region |
| ICD-10-CM Code | C92.0 (Acute myeloblastic leukemia) |
| LOINC Code | 79013-4 (NPM1 gene mutations found in Blood or Tissue by Sequencing) |
| DHA Facility License & Address | License No. 1143 • Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians